The investigators are looking at the different impacts of atenolol, verapamil and perindopril on large artery and lv function in marfan syndrome. It is a double-blind, randomised cross-over trial.
The investigators recruited 21 patients with confirmed diagnosis of Marfan syndrome from two centres. The investigators performed radial artery applanation tonometry and pulse wave analysis to derive central aortic pressure and haemodynamic indexes pre-and post administering Atenolol 75mg, Perindopril 4mg and Verapamil 240mgs each for four weeks with a two week wash-out between medications. All patients underwent detailed functional and anatomical echocardiographic assessments at each visit. Inclusion criteria were ages 16-60 years with no treatment or β-blocker or other monotherapy only for Marfan syndrome. Patients with previous aortic dissection or aortic surgery, severe valvular regurgitation, aortic diameter at the sinotubular junction ≥ 5.0cm, contraindications to specific drug treatment, e.g. asthma and β-blocker, or those who were pregnant or at risk of pregnancy were excluded.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
18
Wales Heart Research Institute, Cardiff University
Cardiff, United Kingdom
CENTRAL ARTERIAL PRESSURE
CENTRAL ARTERIAL PRESSURE MEASURED BY APPLANATION TONOMETRY
Time frame: 18 weeks
LARGE ARTERIAL STIFFNESS INDICES
MEASURED BY ECHO AND BY PULSE WAVE VELOCITY/ANALYSIS BY APPLANATION TONOMETRY
Time frame: 18 WEEKS
LV Function
GLOBAL AND REGIONAL MARKERS BY ECHO
Time frame: 18 WEEKS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.